Transgene

Transgene Debt Growth

The Year-over-Year Debt Growth of Transgene (TNG.PA) as of Nov 18, 2026 is -40.53 %. In the previous year, Year-over-Year Debt Growth was 27.29 % — a change of -248.52% (lower).

Debt Growth

-40.53 %

YoY

-248.52%

Last updated:

Year-over-Year Debt Growth of Transgene is 2024 -40.53 % . Year-over-Year Debt Growth of Transgene was 2023 27.29 % . It decreases by -248.52% lower compared to the previous year.

The Transgene Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2017
-6.78 EUR
Jan 1, 2018
-40.60 EUR
Jan 1, 2019
-36.45 EUR
Jan 1, 2020
-67.82 EUR
Jan 1, 2021
-24.98 EUR
Jan 1, 2022
251.61 EUR
Jan 1, 2023
27.29 EUR
Jan 1, 2024
-40.53 EUR
The Transgene Debt Growth history
YEARDebt GrowthYoY
-40.53 %-248.52%
27.29 %-89.16%
251.61 %-1,107.24%
-24.98 %-63.17%
-67.82 %+86.07%
-36.45 %-10.22%
-40.60 %+499.01%
-6.78 %-127.94%
24.25 %+4,269.28%
0.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Year-over-Year Debt Growth of Transgene is -40.53 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Transgene since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Transgene

All Key Metrics — Transgene